mCRPC (Metastatic Castration-resistant Prostate Cancer)
Oncology·MeSH: Urogenital Neoplasms
Prevalence
256.0 / 100K
Incidence
111.0 / 100K/yr
0 drugs in development·0 companies·3 clinical trials
Frequently asked questions
How many clinical trials target mCRPC (Metastatic Castration-resistant Prostate Cancer)?
There are 3 clinical trials targeting mCRPC (Metastatic Castration-resistant Prostate Cancer) tracked by BioSniper.
What is the prevalence of mCRPC (Metastatic Castration-resistant Prostate Cancer)?
The estimated prevalence of mCRPC (Metastatic Castration-resistant Prostate Cancer) is approximately 256.0 per 100,000 population.
Deep-dive into mCRPC (Metastatic Castration-resistant Prostate Cancer)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis